OneMedNet and Palantir Partner for Healthcare AI and RWD
OneMedNet & Palantir use AI to quickly analyze huge amounts of secure patient data, speeding up medical research and lowering costs.
/ 1680 items
#XY↓
Invivyd Advances VYD2311: New Choice for COVID Protection
Invivyd is developing VYD2311, a non-vaccine antibody, to prevent COVID. Two key trials (DECLARATION/LIBERTY) will test its safety and effectiveness vs. placebo and mRNA vaccines, aiming to offer a flexible new choice for protection.
Novo Nordisk Bets on Telehealth to Relaunch its Weight-Loss Dominance with "Wegovy-in-a-Pill"
Novo Nordisk is planning a strategic digital launch for its forthcoming obesity pill, targeting telehealth sites like Ro and WeightWatchers in early 2026 to recapture market share lost to rival Eli Lilly and combat the rise of copycat drugs.
ALTO-101 Receives FDA Fast Track for CIAS Treatment
Alto Neuroscience has received FDA Fast Track designation for ALTO-101, a potential new treatment for the cognitive difficulties—like poor memory and focus—that millions of schizophrenia patients experience, for which there are currently no approved options.
Big Boost for Ocular Therapeutix Stock and Drug Forecast
Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.
Ovid Therapeutics Secures Major Funding & Announces Positive Drug Trial Results
Ovid Therapeutics secured up to $175 million in financing to fund its clinical pipeline into 2028. The company also reported positive Phase 1 results for OV329, a next-generation epilepsy drug candidate.